Illumina Soars After Crushing Expectations for Q2
In response an upbeat second-quarter report and bullish guidance, shares of Illumina (NASDAQ: ILMN), a leading provider of genetic testing equipment, rose Wednesday morning. The stock was up by 13.3% as of 12:11 p.m. EDT.
Here's are the highlights from Illumina's second quarter:
Management credited the strong Q2 performance to huge demand for the company's new NovaSeq platform. Those results also allowed management to raise its guidance for rest of 2017:
Source: Fool.com
Illumina Inc. Aktie
Die Community bevorzugt Illumina Inc., mit deutlich mehr Buy- (27) als Sell-Einschätzungen (4).
Ein Kursziel von 162 € für Illumina Inc. würde eine Steigerung von mehr als 50% gegenüber dem aktuellen Kurs von 107.86 € bedeuten.